Latest News

Many elderly patients with metastatic renal cell carcinoma benefit from targeted therapies

Many elderly patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials to treat the kidney cancer—are seeing overall survival benefits from treatment with targeted therapies, according to a new study from Penn Medicine researchers published this month in JAMA Network Open. Analyzing 13 years of data on Medicare patients, the study found that the patients who received targeted therapies were more medically complex than those who received the older, more toxic treatments that were available earlier in the study period, indicating that newer treatments are offering hope to more people.

Source link

Related posts

Federally funded research drives nearly one-third of U.S. patents, report finds


Most prescribed blood pressure drugs may be less effective than others


Death Toll in Samoa Measles Epidemic Reaches 25


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy